217 related articles for article (PubMed ID: 36859618)
1. Evaluation of thresholding methods for the quantification of [
Kim M; Seifert R; Fragemann J; Kersting D; Murray J; Jonske F; Pomykala KL; Egger J; Fendler WP; Herrmann K; Kleesiek J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2196-2209. PubMed ID: 36859618
[TBL] [Abstract][Full Text] [Related]
2. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
5. Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [
Kluge K; Einspieler H; Haberl D; Spielvogel C; Stoiber S; Vraka C; Papp L; Wunsch S; Egger G; Kramer G; Grubmüller B; Shariat S; Hacker M; Kenner L; Haug A
J Nucl Med; 2024 Jan; 65(1):63-70. PubMed ID: 38050125
[TBL] [Abstract][Full Text] [Related]
6. qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using
Gafita A; Bieth M; Krönke M; Tetteh G; Navarro F; Wang H; Günther E; Menze B; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(9):1277-1283. PubMed ID: 30850484
[TBL] [Abstract][Full Text] [Related]
7. Comparison of quantitative whole body PET parameters on [
Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
[TBL] [Abstract][Full Text] [Related]
8. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
9. Semiautomatically Quantified Tumor Volume Using
Seifert R; Herrmann K; Kleesiek J; Schäfers M; Shah V; Xu Z; Chabin G; Grbic S; Spottiswoode B; Rahbar K
J Nucl Med; 2020 Dec; 61(12):1786-1792. PubMed ID: 32332147
[TBL] [Abstract][Full Text] [Related]
10. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
[TBL] [Abstract][Full Text] [Related]
11. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
12. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Tumor Volume Assessment on PSMA PET After
Kind F; Eder AC; Jilg CA; Hartrampf PE; Meyer PT; Ruf J; Michalski K
J Nucl Med; 2023 Apr; 64(4):605-610. PubMed ID: 36302658
[TBL] [Abstract][Full Text] [Related]
14. Role of baseline
Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
[TBL] [Abstract][Full Text] [Related]
15. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [
Seifert R; Kessel K; Schlack K; Weber M; Herrmann K; Spanke M; Fendler WP; Hadaschik B; Kleesiek J; Schäfers M; Weckesser M; Boegemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1200-1210. PubMed ID: 32970216
[TBL] [Abstract][Full Text] [Related]
16. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
17. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.
Seifert R; Kessel K; Schlack K; Weckesser M; Kersting D; Seitzer KE; Weber M; Bögemann M; Rahbar K
Theranostics; 2021; 11(17):8143-8151. PubMed ID: 34373733
[No Abstract] [Full Text] [Related]
18. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prostate-specific membrane antigen expression in locally advanced or metastatic breast carcinoma with 68 Ga-PSMA-11 positron-emission tomography/computed tomography imaging for potential theranostics.
Parghane RV; Suralkar T; Nikam D; Basu S
Nucl Med Commun; 2024 Apr; 45(4):329-337. PubMed ID: 38312049
[TBL] [Abstract][Full Text] [Related]
20. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
